Free Trial
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

BioNTech logo
$102.30 +0.24 (+0.24%)
Closing price 10/13/2025 04:00 PM Eastern
Extended Trading
$102.77 +0.47 (+0.46%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioNTech Stock (NASDAQ:BNTX)

Advanced

Key Stats

Today's Range
$101.25
$109.74
50-Day Range
$96.22
$113.52
52-Week Range
$81.20
$129.27
Volume
1.42 million shs
Average Volume
863,944 shs
Market Capitalization
$24.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$134.32
Consensus Rating
Moderate Buy

Company Overview

BioNTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

BNTX MarketRank™: 

BioNTech scored higher than 43% of companies evaluated by MarketBeat, and ranked 661st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 10 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    BioNTech has a consensus price target of $134.32, representing about 31.3% upside from its current price of $102.30.

  • Amount of Analyst Coverage

    BioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioNTech's stock forecast and price target.
  • Earnings Growth

    Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNTech is -63.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNTech is -63.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNTech has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioNTech's valuation and earnings.
  • Percentage of Shares Shorted

    2.70% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioNTech does not currently pay a dividend.

  • Dividend Growth

    BioNTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.70% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in BioNTech has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioNTech has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for BioNTech this week, compared to 12 articles on an average week.
  • Search Interest

    Only 6 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added BioNTech to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.52% of the stock of BioNTech is held by institutions.

  • Read more about BioNTech's insider trading history.
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
BMO Capital Releases a Buy Rating on BioNTech SE (BNTX)
TD Cowen Sticks to Their Hold Rating for BioNTech SE (BNTX)
See More Headlines

BNTX Stock Analysis - Frequently Asked Questions

BioNTech's stock was trading at $113.95 at the beginning of the year. Since then, BNTX stock has decreased by 10.2% and is now trading at $102.30.

BioNTech SE Sponsored ADR (NASDAQ:BNTX) announced its quarterly earnings results on Monday, August, 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by $0.19. The firm's quarterly revenue was up 102.6% on a year-over-year basis.
Read the conference call transcript
.

BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others.

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech's top institutional shareholders include Voya Investment Management LLC (0.01%) and GAMMA Investing LLC.

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/04/2025
Today
10/14/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BNTX
CIK
1776985
Employees
6,772
Year Founded
2008

Price Target and Rating

High Price Target
$171.44
Low Price Target
$110.00
Potential Upside/Downside
+31.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$719.92 million
Net Margins
-12.20%
Pretax Margin
-13.81%
Return on Equity
-1.84%
Return on Assets
-1.59%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.61
Quick Ratio
8.48

Sales & Book Value

Annual Sales
$2.98 billion
Price / Sales
8.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$87.61 per share
Price / Book
1.17

Miscellaneous

Outstanding Shares
240,400,000
Free Float
194,242,000
Market Cap
$24.59 billion
Optionable
Optionable
Beta
1.45

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:BNTX) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners